Fig. 3From: Nafamostat reduces systemic inflammation in TLR7-mediated virus-like illnessR848 causes a depletion in circulating leukocytes, which is partially restored by nafamostat. Male, CD-1 mice received an intraperitoneal injection of R848 (200 μg, dissolved in DMSO and sterile saline) or control solution (DMSO diluted in sterile saline), together with an intravenous injection of nafamostat (3 mg/kg) or vehicle (sterile saline). Blood was collected 6-h post-challenge and total concentration of total white blood cells (A), as well as the concentrations of lymphocytes (B), monocytes (C), neutrophils (D), basophils (E) and eosinophils (F), specifically, were measured. Naïve animals were included to establish baseline (dotted line). Data presented as mean ± SEM, n = 4–10/group, and analysed by two-way ANOVA, **p < 0.01 main effect, #p < 0.05, ##p < 0.01 control vs. R848 with Sidak’s post-hoc test, &p < 0.05 vehicle vs. nafamostat with Sidak’s post-hoc testBack to article page